FOCUS Trial: First Interim Analysis

FOCUS Trial: First Interim Analysis

AnnualMeeting2017

2 years
759 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Krishnansu S. Tewari, MD of University of California, Irvine discusses the most recent results from the FOCUS trial, including the first interim analysis which evaluated the safety of the drug as well as early signs of efficacy. The trial is sponsored by Mateon Therapeutics in South San Francisco, CA This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Up Next Autoplay
National Brain Tumor Society to Provide Funding for ONC201 Trial in EGFR-Independent High-Grade Gliomas
National Brain Tumor Society to Provide Funding for ONC201 Trial in EGFR-Independent High-Grade Gliomas
Category: Acute Lymphoblastic Leukemia
2 Views
alexvarney 19 hours
Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Category: News
1 Views
Cancer-News 20 hours
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
1 Views
cancergrace 4 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
3 Views
Cancer-News 4 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
3 Views
Cancer-News 4 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 4 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
4 Views
Massachusetts General Hospital 4 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
1 Views
Massachusetts General Hospital 4 days